The 4th NextGen therapies of SJIA and MAS, part 4: it is time for IL-18 based trials in systemic juvenile idiopathic arthritis?

Since IL-18 has recently emerged as a biomarker associated with refractory disease course in SJIA, the focus of the discussion was the feasibility of the biomarker-driven drug development to SJIA. Overall, the...

Source: Pediatric Rheumatology - January 5, 2024 Category: Rheumatology Authors: Scott W. Canna and Fabrizio De Benedetti Tags: Meeting report Source Type: research